Dávid Szüts

Principal Intestigator

Research Centre for Natural Sciences
Country flagHungary

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Year:

2026

Year:

2026

Acetaldehyde is the primary metabolite of ethanol, and routes of exposure include endogenous sources, food and cigarette smoke. To explore whether the mutagenic effect of acetaldehyde is responsible for the carcinogenicity of ethanol, we use whole genome sequencing on four human cell lines subjected to long-term, physiologically relevant, analytically validated acetaldehyde treatments. Unexpectedly, the treatments do not induce increased base substitution and short insertion/deletion mutagenesis, nor the appearance of the alcohol-associated cancer mutation signature SBS16. In contrast, we observe large genomic alterations in most cell lines, which parallel the association of 32 kb to 1 Mb deletions and duplications with alcohol consumption in a Japanese gastric cancer cohort. Observations of DNA damage response and a specific requirement for the homologous recombination pathway to tolerate acetaldehyde suggest that DNA breaks are responsible for structural genomic alterations in both cell line and tumour samples, and these may contribute to the carcinogenic effect of acetaldehyde.

Year:

2026

Poly(ADP-ribosyl)ation (PARylation) is a transient post-translational modification catalyzed by PARP enzymes and reversed by the glycohydrolase PARG. Inhibition of PARG causes sustained PARylation, a toxic state that could be exploited for cancer therapy. However, the mechanisms by which excessive PARylation drives toxicity and cell death remain incompletely understood. Here, we examined how persistent PARylation influences cellular responses to replication stress and DNA damage. We found that during replication stress, the decline of ATR checkpoint activity marks the transition from fork stalling to fork collapse, a context in which stabilized poly(ADP-ribose) reduces chromatin-bound RPA. This loss of RPA, a key activator of the checkpoint, further reduces ATR signaling, revealing a feedback loop between unrestrained PARylation and checkpoint control. Our results identify a checkpoint-dependent consequence of unregulated PARP activity during fork collapse and highlight the PARylation-RPA axis as a critical determinant of PARG inhibitor cytotoxicity.

Year:

2025

Year:

2024

Planarians are organisms with a unique capacity to regenerate any part of their body. New tissues are generated in a process that requires many swift cell divisions. How costly is this process to an animal in terms of mutational load remains unknown. Using whole genome sequencing, we defined the mutational profile of the process of regeneration in the planarian species Schmidtea polychroa. We assembled de novo the genome of S. polychroa and analyzed mutations in animals that have undergone regeneration. We observed a threefold increase in the number of mutations and an altered mutational spectrum. High allele frequencies of subclonal mutations in regenerated animals suggested that most of the cells in the regenerated animal were descendants of a small number of stem cells with high expansion potential. We provide, for the first time, the draft genome assembly of S. polychroa, an estimation of the germline mutation rate for a planarian species and the mutational spectrum of the regeneration process of a living organism.

Year:

2024

We analyzed genomic data derived from the prostate cancer of African and European American men in order to identify differences that may contribute to racial disparity of outcome and that could also define novel therapeutic strategies. In addition to analyzing patient derived next generation sequencing data, we performed FISH based confirmatory studies of Chromodomain helicase DNA-binding protein 1 ( CHD1 ) loss on prostate cancer tissue microarrays. We created CRISPR edited, CHD1 deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis. We found that subclonal deletion of CHD1 is nearly three times as frequent in prostate tumors of African American men than in men of European ancestry and it associates with rapid disease progression. We further showed that CHD1 deletion is not associated with homologous recombination deficiency associated mutational signatures in prostate cancer. In prostate cancer cell line models CHD1 deletion did not induce HR deficiency as detected by RAD51 foci formation assay or mutational signatures, which was consistent with the moderate increase of olaparib sensitivity. CHD1 deficient prostate cancer cells, however, showed higher sensitivity to talazoparib. CHD1 loss may contribute to worse outcome of prostate cancer in African American men. A deeper understanding of the interaction between CHD1 loss and PARP inhibitor sensitivity will be needed to determine the optimal use of targeted agents such as talazoparib in the context of castration resistant prostate cancer.

Year:

2024

Year:

2023

Year:

2023

Collaborators (3)

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

Alan D'Andrea

Director, Center for DNA Damage and Repair

Dana-Farber Cancer Institute

UNITED STATES
View details

István Csabai

-

HUNGARY
View details